SeaStar Medical will report Q3 financial results on November 13, 2025, followed by a conference call and webcast.
Quiver AI Summary
SeaStar Medical Holding Corporation, a healthcare company specializing in treatments for critically ill patients facing organ failure, has announced that it will release its third quarter financial results after market close on November 13, 2025. Following the release, the company will host a conference call and webcast at 4:30 p.m. ET to discuss the results and business updates. SeaStar's first commercial product, the QUELIMMUNE (SCD-PED) therapy, is FDA-approved for treating life-threatening acute kidney injury in critically ill pediatric patients. The Selective Cytopheretic Device (SCD) technology has also received Breakthrough Device Designation for several conditions, and the company is currently conducting a pivotal trial in adults with acute kidney injury requiring continuous renal replacement therapy. More details can be found on their website.
Potential Positives
- Announcement of upcoming third quarter financial results provides transparency and engages investors, indicating the company is actively communicating its financial health.
- Approval of the QUELIMMUNE therapy by the FDA highlights the company's innovation and reinforces its position in the market for treating critically ill pediatric patients.
- Breakthrough Device Designation for six therapeutic indications suggests a significant competitive advantage, potentially leading to faster market access and favorable reimbursement conditions.
- The ongoing pivotal trial for adult patients with AKI demonstrates the company's commitment to expanding its treatment options, addressing a critical unmet medical need impacting a substantial patient population.
Potential Negatives
- Company has not yet reported third quarter financial results, raising concerns about its current financial health.
- QUELIMMUNE therapy is the only FDA-approved product for a very niche indication, which may limit market potential and revenue generation.
- While the company has received Breakthrough Device Designation, it is still reliant on ongoing trials and future approvals, which introduces uncertainty regarding future success and profitability.
FAQ
When will SeaStar Medical report its third quarter financial results?
SeaStar Medical will report its third quarter financial results on Thursday, November 13, 2025, after market close.
How can I join SeaStar Medical's conference call?
You can join the conference call by pre-registering online to receive a phone number and unique passcode.
What is SeaStar Medical's main focus?
SeaStar Medical focuses on transforming treatments for critically ill patients facing organ failure and potential loss of life.
What is the QUELIMMUNE therapy?
QUELIMMUNE is SeaStar Medical’s FDA-approved therapy for life-threatening acute kidney injury in critically ill pediatric patients.
What is the significance of the Selective Cytopheretic Device (SCD)?
The SCD is pivotal in SeaStar Medical's therapies and has received Breakthrough Device Designation for multiple therapeutic indications.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ICU Insider Trading Activity
$ICU insiders have traded $ICU stock on the open market 7 times in the past 6 months. Of those trades, 7 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ICU stock by insiders over the last 6 months:
- HEEL KENNETH VAN has made 2 purchases buying 35,000 shares for an estimated $30,812 and 0 sales.
- JENNIFER A BAIRD has made 2 purchases buying 20,000 shares for an estimated $16,989 and 0 sales.
- JOHN NEUMAN purchased 40,000 shares for an estimated $14,396
- KEVIN CHUNG (Chief Medical Officer) has made 2 purchases buying 14,500 shares for an estimated $13,625 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ICU Hedge Fund Activity
We have seen 1 institutional investors add shares of $ICU stock to their portfolio, and 1 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TYCHE WEALTH PARTNERS LLC removed 20,000 shares (-53.1%) from their portfolio in Q3 2025, for an estimated $11,399
- SBI SECURITIES CO., LTD. added 55 shares (+59.1%) to their portfolio in Q3 2025, for an estimated $31
- WHITTIER TRUST CO added 0 shares (+0.0%) to their portfolio in Q3 2025, for an estimated $0
- TD WATERHOUSE CANADA INC. added 0 shares (+0.0%) to their portfolio in Q3 2025, for an estimated $0
- TSFG, LLC added 0 shares (+0.0%) to their portfolio in Q3 2025, for an estimated $0
- GAME PLAN FINANCIAL ADVISORS, LLC added 0 shares (+0.0%) to their portfolio in Q3 2025, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
DENVER, Nov. 05, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its third quarter financial results after market close on Thursday, November 13, 2025, and host a webcast and conference call to discuss its financial results and business progress.
| Date/Time: | Thursday, November 13, 2025, at 4:30 p.m. ET / 2:30 p.m. MT |
| Webcast: | The live webcast and replay can be found here . |
| Dial-in number: | To join the conference call via phone, please pre-register online here to receive a telephone number and unique passcode required to enter the call. |
| A replay of the webcast will be available after 7:30 pm ET and can be accessed here . | |
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The QUELIMMUNE (SCD-PED) therapy is SeaStar Medical’s first commercial product based on its patented Selective Cytopheretic Device (SCD) technology. The QUELIMMUNE (SCD-PED) therapy was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X .
Contact:
SeaStar Investor Relations:
[email protected]
